Current status and future of anti-angiogenic drugs in lung cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Remon J, Lacas B, Herbst R, et al. ANtiangiogenic second-line lung cancer meta-analysis on individual patient data in non-small cell lung cancer: ANSELMA. Eur J Cancer. 2022;166:112–25.
Manzo A, Montanino A, Carillio G, et al. Angiogenesis inhibitors in NSCLC. Int J Molecul Sci. 2017;18(10):2021.
Choi SH, Yoo SS, Lee SY, Park JY. Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer. Arch Pharmacal Res. 2022;45(4):263–79.
Tirpe A, Gulei D, Tirpe GR, et al. Beyond conventional: the new horizon of anti-angiogenic micrornas in non-small cell lung cancer therapy. Int J Molecul Sci. 2020;21(21):8002.
Reck M, Garassino MC, Imbimbo M, et al. Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. Lung Cancer (Amsterdam, Netherlands). 2018;120:62–9.
Ramadan WS, Zaher DM, Altaie AM, Talaat IM, Elmoselhi A. Potential therapeutic strategies for lung and breast cancers through understanding the anti-angiogenesis resistance mechanisms. Int J Molecul Sci. 2020: 21(2)
Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58–62.
Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86: 102017.
Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50.
Hsu WH, Yang JC, Mok TS, Loong HH. Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol. 2018;29(21):i3–9.
Wakelee HA, Dahlberg SE, Keller SM, et al. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2017;18(12):1610–23.
Lynch TJ, Spigel DR, Brahmer J, et al. Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study. J Thoracic Oncol Off Publ Int Assoc Study Lung Cancer. 2014;9(9):1332–9.
Soria JC, Mauguen A, Reck M, et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol Off J Eur Soc Med Oncol. 2013;24(1):20–30.
Hu H, Chen Y, Tan S, et al. The Research progress of antiangiogenic therapy, immune therapy and tumor microenvironment. Front Immunol. 2022;13: 802846.
Ren S, Xiong X, You H, Shen J, Zhou P. The combination of immune checkpoint blockade and angiogenesis inhibitors in the treatment of advanced non-small cell lung cancer. Front Immunol. 2021;12: 689132.
Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7(5):387–401.
Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383(14):1328–1339.
Ferrara R, Imbimbo M, Malouf R, et al. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Cochrane Database Syst Rev. 2021;4(4):CD013257.
Liu X. Effectiveness of bevacizumab in combination with gefitinib for EGFR mutation-positive advanced non-small cell lung cancer. China Modern Drug Appl. 2021;15(02):173–5 (In Chinese).
Du L, Shi X. Meta-analysis of the efficacy and safety of EGFR-TKIs in combination with bevacizumab in the treatment of non-small cell lung cancer. Mod Med Oncol. 2021;29(17):3016–22 (In Chinese).
Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med. 2011;364(10):947–55.
Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20(5):625–35.
Yu HA, Schoenfeld AJ, Makhnin A, et al. Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers: a phase 1/2 single-group open-label trial. JAMA Oncol. 2020;6(7):1048–54.
Qi C, Cui H, Chen D. Combination of osimertinib and bevacizumab as first-line treatment for patients with metastatic EGFR-mutant lung cancers. JAMA Oncol. 2020;6(12):1982.
Zhao Y, Liu J, Cai X, et al. Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis. BMJ. 2019;367: l5460.
Turkes F, Chau I. Ramucirumab and its use in the treatment of hepatocellular carcinoma. Future Oncol (London, England). 2019;15(9):979–88.
Le X, Nilsson M, Goldman J, et al. Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC. J Thoracic Oncol Off Publ Int Assoc Study Lung Cancer. 2021;16(2):205–15.
Nakagawa K, Garon EB, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(12):1655–69.
Nadal E, Horinouchi H, Shih J-Y, et al. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, epidermal growth factor receptor Mutation-Positive, metastatic non-small-cell lung cancer: safety profile and manageability. Drug Saf. 2022;45(1):45–64.
Cao Y, Zhang W, Zhang J. Advances in the application of ramucirumab in molecularly targeted tumor therapy. China Pharmacy. 2017;28(11):1577–80 (In Chinese).
Camidge DR, Berge EM, Doebele RC, et al. A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol. 2014;9(10):1532–9.
Garon EB, Scagliotti GV, Gautschi O, et al. Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy. ESMO Open. 2020;5(1):e000567.
Padda SK, Reckamp KL. Combination of immunotherapy and antiangiogenic therapy in cancer-a rational approach. J Thoracic Oncol: Off Publ Int Assoc Study Lung Cancer. 2021;16(2):178–82.
Garon EB. Osimertinib plus ramucirumab: The best of both worlds? Clin Cancer Res Off J Am Assoc Cancer Res. 2021;27(4):905–7.
Herbst RS, Arkenau H-T, Santana-Davila R, et al. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Lancet Oncol. 2019;20(8):1109–23.
Klempner SJ, Wainberg ZA. Ramucirumab plus pembrolizumab: can we make the maths work? Lancet Oncol. 2019;20(8):1041–3.
Reckamp KL, Redman MW, Dragnev KH, et al. Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small-cell lung cancer previously treated with immunotherapy-lung-MAP S1800A. J Clin Oncol Off J Am Soc Clin Oncol. 2022;40(21):2295–306.
Takeda M, Sakai K, Okamoto K, et al. Genome sequencing for nonsmall-cell lung cancer identifies a basis for nintedanib sensitivity. Ann Oncol Off J Eur Soc Med Oncol. 2016;27(4):748–50.
Gabasa M, Ikemori R, Hilberg F, Reguart N, Alcaraz J. Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients. Br J Cancer. 2017;117(8):1128–38.
Doebele RC, Conkling P, Traynor AM, et al. A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol Off J Eur So Med Oncol. 2012;23(8):2094–102.
Reck M, Kaiser R, Eschbach C, et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol Off J Eur Soc Med Oncol. 2011;22(6):1374–81.
Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15(2):143–55.
Tu J, Xu H, Ma L, et al. Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells. Theranostics. 2022;12(2):747–66.
Lu J, Zhong H, Chu T, et al. Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy. Eur Respir J. 2019;53(3):1801562.
Han B, Li K, Wang Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 2018;4(11):1569–75.
Chen XZ. Anlotinib for refractory advanced non-small cell lung cancer in China. JAMA Oncol. 2019;5(1):116–7.
Zhou M, Chen X, Zhang H, et al. China national medical products administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy. Cancer Commun (Lond). 2019;39(1):36.
Fan P, Qiang H, Liu Z, et al. Effective low-dose anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy. Front Immunol. 2022;13: 937924.
Zhang X, Zeng L, Li Y, et al. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China. Cancer Immunol Immunother CII. 2021;70(9):2517–28.
Yang Y, Li L, Jiang Z, Wang B, Pan Z. Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer. Cancer Immunol Immunother CII. 2020;69(12):2523–32.
Chu T, Zhong R, Zhong H, et al. Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC. J Thorac Oncol. 2021;16(4):643–52.
Yuan M, Zhai Y, Men Y, et al. Anlotinib enhances the antitumor activity of high-dose irradiation combined with Anti-PD-L1 by potentiating the tumor immune microenvironment in murine lung cancer. Oxid Med Cell Longev. 2022;2022:5479491.
Xiang M, Yang X, Ren S, et al. Anlotinib combined with S-1 in third- or later-line stage IV non-small cell lung cancer treatment: a phase II clinical trial. Oncologist. 2021;26(12):e2130–5.
Zhang W, Deng P, Kong T, et al. Safety and efficacy of anlotinib in combination with standard chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a multi-center, prospective study (ACTION-2). Lung Cancer (Amsterdam, Netherlands). 2022;173:43–8.
Mukhopadhyay S, Pennell NA, Ali SM, et al. RET-rearranged lung adenocarcinomas with lymphangitic spread, psammoma bodies, and clinical responses to cabozantinib. J Thoracic Oncol Off Publ Int Assoc Study Lung Cancer. 2014;9(11):1714–9.
Leone JP, Duda DG, Hu J, et al. A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. Breast Cancer Res Treat. 2020;179(1):113–23.
Neal JW, Dahlberg SE, Wakelee HA, et al. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol. 2016;17(12):1661–71.
Drilon A, Rekhtman N, Arcila M, et al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncol. 2016;17(12):1653–60.
Kang J, Chen H-J, Wang Z, et al. Osimertinib and cabozantinib combinatorial therapy in an EGFR-mutant lung adenocarcinoma patient with multiple MET secondary-site mutations after resistance to crizotinib. J Thoracic Oncol Off Publ Int Assoc Study Lung Cancer. 2018;13(4):e49–53.
Sun TY, Niu X, Chakraborty A, Neal JW, Wakelee HA. Lengthy progression-free survival and intracranial activity of cabozantinib in patients with crizotinib and ceritinib-resistant ROS1-positive non-small cell lung cancer. J Thoracic Oncol Off Publ Int Assoc Study Lung Cancer. 2019;14(2):e21–4.
Klempner SJ, Borghei A, Hakimian B, Ali SM, Ou S-HI. Intracranial activity of cabozantinib in MET exon 14-positive NSCLC with brain metastases. J Thoracic Oncol Off Publ Int Assoc Study Lung Cancer. 2017;12(1):152–6.
Lu S, Li L, Luo Y, et al. A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer. J Thorac Oncol. 2015;10(1):206–11.
Shi S, Wang R, Chen Y, et al. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models. PLoS ONE. 2013;8(6): e65757.
Chen L, Tong F, Peng L, et al. Efficacy and safety of recombinant human endostatin combined with whole-brain radiation therapy in patients with brain metastases from non-small cell lung cancer. Radiother Oncol. 2022;174:44–51.
Zhao X, Wen X, Wei W, et al. Predictors for the efficacy of Endostar combined with neoadjuvant chemotherapy for stage IIIA (N2) NSCLC. Cancer Biomark. 2017;21(1):169–77.
Wang Z, Zhang H, Zhou C, et al. Real-world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non-driver gene mutation advanced non-small cell lung cancer. Cancer Med. 2019;8(4):1434–41.
Shi X, Dong X, Young S, et al. The impact of angiogenesis inhibitors on survival of patients with small cell lung cancer. Cancer Med. 2019;8(13):5930–8.
Zhu J, Chen G, Niu K, et al. Efficacy and safety of recombinant human endostatin during peri-radiotherapy period in advanced non-small-cell lung cancer. Future Oncol (London, England). 2022;18(9):1077–87.
Wu J, Zhao X, Sun Q, et al. Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model. Biomed Pharmacother Biomed Pharmacother. 2020;125:109746.
Hamberg P, Verweij J, Sleijfer S. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist. 2010;15(6):539–47.
Katakami N, Felip E, Spigel DR, et al. A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician’s choice in patients with advanced non-small cell lung cancer. Ann Oncol Off J Eur Soc Med Oncol. 2017;28(9):2241–7.
Duda DG, Jain RK. Revisiting antiangiogenic multikinase inhibitors in the era of immune checkpoint blockade: the case of sorafenib. Can Res. 2022;82(20):3665–7.
Tiseo M, Franciosi V, Ardizzoni A. Multi-target inhibitors in non-small cell lung cancer (NSCLC). Ann Oncol Off J Eur Soc Med Oncol. 2006;17(2):55–7.
Zhao H, Yao W, Min X, et al. Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant NSCLC: the phase III ACTIVE Study (CTONG1706). J Thoracic Oncol Off Publ Int Assoc Study Lung Cancer. 2021;16(9):1533–46.
Zhang Z, Luo F, Zhang Y, et al. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706). Cancer Commun (London, England). 2019;39(1):69.
Wu F, Zhang S, Gao G, et al. Successful treatment using apatinib with or without docetaxel in heavily pretreated advanced non-squamous non-small cell lung cancer: a case report and literature review. Cancer Biol Ther. 2018;19(3):141–4.
Ding L, Li Q-J, You K-Y, Jiang Z-M, Yao H-R. The use of apatinib in treating nonsmall-cell lung cancer: case report and review of literature. Medicine. 2016;95(20): e3598.
Baggstrom MQ, Socinski MA, Wang XF, et al. Maintenance sunitinib following initial platinum-based combination chemotherapy in advanced-stage IIIB/IV non-small cell lung cancer: a randomized, double-blind, placebo-controlled phase III study-CALGB 30607 (Alliance). J Thoracic Oncol Off Publ Int Assoc Study Lung Cancer. 2017;12(5):843–9.
Cooper AJ, Kobayashi Y, Kim D, et al. Identification of a RAS-activating TMEM87A-RASGRF1 fusion in an exceptional responder to sunitinib with non-small cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2020;26(15):4072–9.
Weng M-C, Li M-H, Chung JG, et al. Apoptosis induction and AKT/NF-κB inactivation are associated with regroafenib-inhibited tumor progression in non-small cell lung cancer in vitro and in vivo. Biomed Pharmacother Biomed Pharmacother. 2019;116:109032.
King JW, Lee S-M. Axitinib for the treatment of advanced non-small-cell lung cancer. Expert Opin Investig Drugs. 2013;22(6):765–73.
Kozloff MF, Martin LP, Krzakowski M, et al. Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. Br J Cancer. 2012;107(8):1277–85.
Twelves C, Chmielowska E, Havel L, et al. Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer. Ann Oncol Off J Eur Soc Med Oncol. 2014;25(1):132–8.
Sun Q, Zhou J, Zhang Z, et al. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635–45.
Lu S, Chen G, Sun Y, et al. A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer: the FALUCA study. Lung Cancer (Amsterdam, Netherlands). 2020;146:252–62.
Lu S, Chang J, Liu X, et al. Randomized, double-blind, placebo-controlled, multicenter phase II study of fruquintinib after two prior chemotherapy regimens in chinese patients with advanced nonsquamous non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(12):1207–17.
Garon EB, Ciuleanu T-E, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet (London, England). 2014;384(9944):665–73.
Cheng G, Jiang X, Liu H, et al. Efficacy and safety of anlotinib in combination with chemotherapy in the second-line treatment of advanced non-small cell lung cancer. Mod Med Oncol. 2022;30(14):2534–8 (In Chinese).
Cortot AB, Audigier-Valette C, Molinier O, et al. Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study. Eur J Cancer. 2020;131:27–36.
Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol Off J Eur Soc Med Oncol. 2007;18(5):945–9.
Zhao W-Y, Chen D-Y, Chen J-H, Ji Z-N. Effects of intracavitary administration of Endostar combined with cisplatin in malignant pleural effusion and ascites. Cell Biochem Biophys. 2014;70(1):623–8.
Zhou Z, Li H, Hu D, Xie L. Clinical efficacy of bevacizumab combined with cisplatin in the treatment of malignant pleural effusion and ascites caused by lung cancer: a randomized trial. Ann Palliat Med. 2021;10(10):10575–83.
Xiang Z, Deng X, He W, et al. Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy. Ann Med. 2022;54(1):1357–71.
Masago K, Fujimoto D, Fujita S, et al. Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer. Molecul Clin Oncol. 2015;3(2):415–9.
Fang S-C, Zhang H-T, Hu H-D, Wang C-Y, Zhang Y-M. Effect of Endostar combined with angiopoietin-2 inhibitor on malignant pleural effusion in mice. Med Oncol (Northwood, London, England). 2015;32(1):410.
Biaoxue R, Xiguang C, Hua L, Wenlong G, Shuanying Y. Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: a systematic evaluation and meta-analysis. BMC Cancer. 2016;16(1):888.
Chen Y, Mathy NW, Lu H. The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non-small cell lung cancer (Review). Mol Med Rep. 2018;17(6):8019–30.
Marquez-Medina D, Popat S. Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases. Clin Trans Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mexico. 2016;18(8):760–8.
Li B. Clinical study on the inhibition of malignant pleural effusion in non-small cell lung cancer by high-dose endostar single agent thoracic perfusion. University of South China; 2021. (In Chinese).
Ma X, Yao Y, Yuan D, et al. Recombinant human endostatin endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice. PLoS ONE. 2012;7(12): e53449.
Guo B, Chen Z, Zheng Q. Effectiveness of different doses of Endostar combined with cisplatin for the treatment of malignant pleural effusion in non-small cell lung cancer by thoracic perfusion. Qilu Medi J. 2016;31(02):148–51 (In Chinese).
He J, Gou J, Zhai M, Zheng X, et al. Evaluation of the efficacy of Endostar combined with intrapleural local administration of cisplatin in the treatment of malignant pleural effusion in non-small cell lung cancer. Int J Respir. 2016;36(15):1127–30 (In Chinese).
Kitamura K, Kubota K, Ando M, et al. Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion. Cancer Chemother Pharmacol. 2013;71(2):457–61.
Jiang L, Li P, Gong Z, et al. Effective treatment for malignant pleural effusion and ascites with combined therapy of bevacizumab and cisplatin. Anticancer Res. 2016;36(3):1313–8.
Zhou J. Meta-analysis of bevacizumab combined with chemotherapy intrathoracic administration for malignant thoracoabdominal effusion. Lanzhou University; 2020. (In Chinese).
Chen D, Song X, Shi F, et al. Greater efficacy of intracavitary infusion of bevacizumab compared to traditional local treatments for patients with malignant cavity serous effusion. Oncotarget. 2017;8(21):35262–71.
Orecchia P, Conte R, Balza E, et al. Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts. Oncotarget. 2015;6(35):37426–42.
Pisarsky L, Bill R, Fagiani E, et al. Targeting metabolic symbiosis to overcome resistance to anti-angiogenic therapy. Cell Rep. 2016;15(6):1161–74.
Allen E, Miéville P, Warren CM, et al. Metabolic symbiosis enables adaptive resistance to anti-angiogenic therapy that is dependent on mTOR signaling. Cell Rep. 2016;15(6):1144–60.
Horvath L, Thienpont B, Zhao L, Wolf D, Pircher A. Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC): novel approaches and future outlook. Mol Cancer. 2020;19(1):141.
Chung AS, Wu X, Zhuang G, et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med. 2013;19(9):1114–23.